SEC Form 4 · accession 0001179110-18-013566
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura J Schumacher
Officer — Executive Vice President
Period of report
Dec 4, 2018
Accepted (ET)
Dec 7, 2018 · 5:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.01 par value | Dec 4, 2018 | M | 94,140 | $51.42 | A | 192,398 | D | |
| Common stock, $0.01 par valueF1 | Dec 4, 2018 | S | 33,198 | $94.3418 | D | 159,200 | D | |
| Common stock, $0.01 par valueF2 | Dec 4, 2018 | S | 41,642 | $93.6647 | D | 117,558 | D | |
| Common stock, $0.01 par valueF3 | Dec 4, 2018 | S | 10,000 | $92.3705 | D | 107,558 | D | |
| Common stock, $0.01 par valueF4 | Dec 4, 2018 | S | 9,300 | $91.7745 | D | 98,258 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (Right to buy)F5 | $51.42 | Dec 4, 2018 | M | 94,140 | D | Feb 20, 2015 | Feb 19, 2024 | Common Stock | 94,140 | 0 | D |
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.98 to $94.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.98 to $92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.515 to $92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Remarks
The transactions reported on this Form 4 were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).